praluent

Alirocumab

Products Alirocumab was approved in the United States and EU in 2015 and in many countries in 2016 as the first agent in the group of PCSK9 inhibitors in the form of a solution for injection (Praluent). Structure and properties Alirocumab is an IgG1 monoclonal antibody with a molecular mass of 146 kDa. Effects Alirocumab … Alirocumab

PCSK9 Inhibitors

Products Alirocumab was approved in the United States in 2015 as the first agent in the group of PCSK9 inhibitors in the form of a solution for injection (Praluent). Evolocumab (Repatha) followed as the second agent in the EU, also in 2015. Structure and properties PCSK9 inhibitors to date are monoclonal antibodies that must be … PCSK9 Inhibitors